In less than a decade, a transposon (*Tn*4401)-mediated outbreak of *bla*~KPC~-producing *Klebsiella pneumoniae* has disseminated worldwide \[[@OFV213C1]--[@OFV213C3]\]. In most regions, a predominant carbapenem-resistant *K pneumoniae* (CRKP) strain, designated as ST258 by multilocus sequence typing (MLST), and harboring *bla*~KPC~ \[[@OFV213C1]--[@OFV213C4]\] is found. Therefore, the epidemiological investigations on the CRKP pandemic focuses almost exclusively on *bla*~KPC~-producing ST258 CRKP strains \[[@OFV213C1], [@OFV213C2]\]. However, resistance to carbapenems is also seen among other sequence types (STs) of *K pneumoniae*, and it is mediated by various other mechanisms of resistance (non-*bla*~KPC~) \[[@OFV213C5]\]. Carbapenemases such as *bla*~VIM~, *bla*~IMP~, *bla*~NDM~, and *bla*~OXA-48~ rapidly emerged in clinical strains of *K pneumoniae* in the United States \[[@OFV213C6]--[@OFV213C9]\] and worldwide \[[@OFV213C10]--[@OFV213C12]\]. Moreover, other mechanisms of resistances to carbapenems, not mediated through carbapenemase production but through production of extended-spectrum β-lactamases (ESBLs) and plasmid-borne AmpCs combined with loss of outer-membrane porins \[[@OFV213C13], [@OFV213C14]\] or efflux pumps \[[@OFV213C15], [@OFV213C16]\], have been reported as well among CRKP.

Many of the diagnostic techniques that are used to investigate CRKP focus on phenotypic tests such as the modified Hodge tests (MHT), which are much less accurate at detecting carbapenemases other than *bla*~KPC~, or limited genotypic (polymerase chain reaction \[PCR\]) tests to *bla*~KPC~ only \[[@OFV213C4], [@OFV213C17], [@OFV213C18]\]. This might result in under diagnosis of CRKP, due to the continued dissemination of non-*bla*~KPC~-producing strains. The evolving epidemiology of CRKP necessitates continued study of its epidemiology (ie, patients′ characteristics and infection outcomes), stratified upon the molecular characteristics of circulating strains. In this study, our aims were to compare the characteristics and outcomes of CRKP ST258 carriers (ie, carriers of the predominant strain) to carriers of other STs defined using MLST.

METHODS {#s2}
=======

Carbapenem-resistant *K pneumoniae* isolates from adult patients, obtained from September 2008 to September 2009, were analyzed at the Detroit Medical Center (DMC). Carbapenem-resistant *K pneumoniae* cases consisted of all patients who had an isolate discovered in a clinical sample, sent from all inpatient and outpatient facilities that submit specimens to DMC Microbiology Laboratory \[[@OFV213C19], [@OFV213C20]\]. Active surveillance screening cultures were not routinely performed during the study period, and they were excluded from the analysis. Cultures from all anatomic sites were collected, and both infected and "colonized-only" patients were enrolled \[[@OFV213C21]\]. For patients who had \>1 CRKP isolate during the study period, only the first episode of CRKP isolation was analyzed \[[@OFV213C19], [@OFV213C20]\]. More than 200 parameters were retrieved from patient charts including demographics, background and comorbid conditions, recent exposures to antimicrobials and to healthcare procedures and environments, acute severity of illness indices, therapeutic regimens, and outcomes \[[@OFV213C19], [@OFV213C20]\]. Patient characteristics were compared between groups using Fisher\'s exact test.

Bacteria were identified to the species level, and susceptibilities were determined to predefined antimicrobials, based on an automated system (MicroScan; Siemens AG, Munich, Germany) and in accordance with Clinical and Laboratory Standards Institute criteria \[[@OFV213C17]\]. Susceptibilities to colistin and tigecycline were determined by using E-tests (bioMérieux Co., Paris, France). Extended-spectrum β-lactamases, after being identified in the automated system, were confirmed with a disc diffusion test \[[@OFV213C17]\]. All *K pneumoniae* that were resistant to 1 or more expanded-spectrum cephalosporin (ie, 3rd or 4th generation) and had a minimum inhibitory concentration ≥2 mg/L to ertapenem were screened for carbapenemase-production with the MHT \[[@OFV213C17]\]. Subsequently, CRKPs were tested by PCR specifically for the presence of *bla*~KPC~, at the Research Services of the Veterans Affairs Medical Center (Cleveland, OH), with previously characterized *K pneumoniae* carbapenemase (KPC)-producing *K pneumoniae* strains used as controls \[[@OFV213C22], [@OFV213C23]\]. Strains that lacked the *bla*~KPC~ initially were tested for the presence of other carbapenemases (*bla*~IMP~, *bla*~VIM~, *bla*~OXA~, *bla*~NDM~) and *bla*~KPC~ again, with a different PCR-based methodology at DMC microbiology laboratory (Verigene; Nanosphere; Northbrook, Illinois, USA). Multilocus sequence typing was conducted to determine ST according to standard protocols using a simplified protocol and universal sequence primers (<http://bigsdb.web.pasteur.fr>) (Pasteur Institute, France) \[[@OFV213C24]\]. Sequence type with 6 of 7 shared alleles (single locus variants) were considered to be within a single clonal complex. Repetitive extragenic palindromic PCR (rep-PCR) using an automated system (DiversiLab, bioMérieux, Paris, France) was performed as previously detailed \[[@OFV213C20]\]. Isolates with band patterns ≥95% similarity were considered genetically related \[[@OFV213C23]\]. Institutional review boards of all participating centers approved the study before its initiation \[[@OFV213C20]\].

RESULTS {#s3}
=======

Seventy CRKPs isolated from 69 patients were typed using MLST. One patient had 2 CRKP strains isolated from a wound on the same day: one was ST258 and the other ST248. This patient was excluded from the analysis. As displayed in the Table [1](#OFV213TB1){ref-type="table"}, 61 patients with CRKP ST258 were compared with 7 patients with other STs (3 with ST514, 2 with ST11, 1 with ST13, and 1 with ST248). All but 1 strain had a positive MHT, indicating the presence of a carbapenemase; the strain with a false-negative MHT was ST258 type. In 55 of 56 ST258 strains that were tested (98%) with *bla*~KPC~ PCR, the presence of *bla*~KPC~ was confirmed, vs 5 (71%) *bla*~KPC~ producers among the non-ST258 strains (*P* = .03 by Fisher\'s exact test). In the additional multiplex PCR test analysis (Verigene), the 2 non-ST258 strains that did not harbor *bla*~KPC~ had no other carbapenemase (ie, *bla*~IMP~, *bla*~VIM~, *bla*~OXA~, *bla*~NDM~). In 1 strain, a *bla*~CTX-M~ ESBL was detected. Table 1.Representative Parameters of the Univariate Analysis Comparing Epidemiological Features and Outcomes of Patients With Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) Clone ST258 to Other CRKP ClonesParameterST258 (n = 61), N (%)Non-ST258 (n = 7), N (%)*P* ValueDemographics Age, years, mean ± SD65.4 ± 15.363.9 ± 15.3.8 Elderly (over 65 y)39 (63.9)3 (42.9).4 Female gender28 (45.9)5 (71.4).3Functional Status and Comorbidities on Admission Residence at any long-term care facility before admission43 (74.1)6 (85.7).50 Dependent functional status upon admission \[[@OFV213C31]\]47 (87.0)5 (83.3)\>.99 Cognitive impairment upon admission26 (48.1)4 (66.7).67 Charlson\'s combined condition score, mean ± SD \[[@OFV213C32]\]7.8 ± 3.48.7 ± 4.4.61Exposure to Healthcare Settings and Antibiotics Before CRKP Isolation Time at risk: days from admission to culture, median (IQR)9 (1--19)8 (2--16).64 Previous hospitalization in the past 3 mo46 (80.7)5 (83.3)\>.99 Regular visits to outpatient clinic22 (38.6)4 (57.1).43 Invasive procedure in past 3 mo49 (89.1)6 (100.0).39 Chronic permanent devices (eg, tracheotomy, gastrostomy, tunneled\
  central-line, urinary catheter, pacemaker/defibrillator, external fixator)48 (88.9)6 (85.7).8 Received antibiotics (any type) in preceding 3 mo46 (98)5 (83).22 Received carbapenems in preceding 3 mo11 (25)2 (50).3Microbiology Body Site of Isolation  Blood14 (23)0 (0).33  Respiratory15 (24.6)3 (42.9).37  Urine23 (37.7)3 (42.9)\>.99  Wound8 (13.1)1 (14.3)\>.99  CSF1 (1.6)0\>.99 Infection (as opposed to asymptomatic colonization)39 (78)4 (66.7).62 Colistin resistance12 (20)2 (28.6).63 Tigecycline resistance12 (20.7)0.33 **Tobramycin resistance57 (100)3 (50).001** **Ciprofloxacin resistance54 (98.2)3 (60).02** Trimethoprim/ sulfamethoxazole resistance49 (86)4 (67).24 Positive modified Hodge test57 (98)7 (100)\>.99 **PCR *bla*~KPC~-positive55 (98.2)5 (71.4).03** **rep-PCR typing**  **Clone 142 (78.6)1 (14.3).002**  Clone 212 (21.4)0.33  **Clone 303 (42.9)\<.001**  **Clone 403 (42.9)\<.001**Severity of Illness Indices at Time of Isolation McCabe score, mean ± SD \[[@OFV213C33]\]2.04 ± 0.661.83 ± 0.41.31 Severe sepsis/septic shock/multiorgan failure8 (20.5)2 (33.3).6 **Received vasopressors3 (7.7)3 (50).02** Acutely transferred to an intensive care unit7 (14.3)3 (42.9).1 **Necessitated intubation4 (11.1)3 (50).05** Infectious clinical syndrome  Colonization, no infection11 (25)2 (33.3).64  Central-line infection5 (11.4)0\>.99  Pneumonia10 (22.7)2 (33.3).62  UTI7 (15.9)2 (33.3).29  Skin/soft tissue infection7 (15.9)0.58  Bone/joint infection1 (2.3)0\>.99  CNS1 (2.3)0\>.99  Bacteremia without focus2 (4.5)0\>.99Antimicrobial therapy Hours to appropriate therapy, median (IQR)97 (76--123)72 (24--120).71 Appropriate therapy options were available55 (92)7 (100).43Outcomes In-hospital mortality14 (26.4)3 (50).34 90-days mortality18 (35.3)4 (66.7).19 For Survivors of Index Hospitalization Only  Functional status deterioration23 (67.6)2 (66.7)\>.99  Discharged to a long-term care facility after being admitted from home27 (77.1)1 (100)\>.99  Additional hospitalizations in the 3 mo after the isolation27 (52.9)4 (66.7).68  Invasive procedure or surgery in the 3 mo after the isolation25 (53.2)4 (80.0).37 Additional isolations of CRKP ("bacteriological failure")28 (50.9)4 (57.1)\>.99 Total length of hospital stay (in days), median (IQR)27 (14--40)18 (12--23).18 Length of stay (days) from culture to discharge, excluding the dead, median (IQR)9 (4--21)10 (5--12).7[^1][^2]

As displayed in the Table [1](#OFV213TB1){ref-type="table"}, patients with CRKP other than ST258 were younger and had more severe indices of acute illness (eg, necessitated vasopressors and acute tracheal intubation during the acute disease course). In addition, ST258 strains were resistant to more classes of antimicrobials (eg, tobramycin, ciprofloxacin) than other strains.

Outcomes did not differ significantly between patients with carriage of a CRKP ST258 strain versus other CRKP strains in this study. Due to low numbers of carriers of non-ST258 strains, multivariable risk factors and/or outcomes analyses were not performed. All but 2 ST258 isolates clustered into 2 related groups by rep-PCR. One group (Figure [1](#OFV213F1){ref-type="fig"}, Key 6--17) was rep-PCR type A, which has been previously reported \[[@OFV213C25]\] and likely corresponds to clade 1 of ST258 \[[@OFV213C26]--[@OFV213C28]\]. The second group (Figure [1](#OFV213F1){ref-type="fig"}, Key 21--62) was rep-PCR type B, which likely corresponds to clade 2. Figure 1.Multilocus sequence typing analysis of carbapenem-resistant *Klebsiella pneumoniae* strains, Detroit Medical Center, Michigan, 2008--2009.

DISCUSSION {#s4}
==========

The epidemiology of CRKP is continually evolving, and it now consists of non-ST258 circulating strains that possess distinct epidemiological features. Despite the low number of patients with non-ST258 CRKP that were enrolled, this analysis clearly stresses that these strains are associated with non-*bla*~KPC~ status. It is notable that 2 of the non-ST258 strains were identified as ST11, which are single-locus variants of ST258 (ST11) and are thought to be precursors of *bla*~KPC~-producing *K pneumoniae* ST258 (1 isolate produced *bla*~KPC~ and 1 did not) \[[@OFV213C27]\].

We acknowledge that this investigation was conducted on strains isolated in 2008--2009, when CRKP was just emerging and disseminating at DMC and Southeast Michigan \[[@OFV213C19], [@OFV213C20], [@OFV213C29]\]. However, in 2013, 125 (15%) of 846 patient-unique *K pneumoniae* clinical isolations at DMC were CRKP; of those, 26 isolates (ie, 21% of all CRKPs) had a negative MHT, which might represent false-negative tests due to the presence of carbapenemases other than KPC. This observation suggests increased diversity in the current molecular epidemiology of CRKP at DMC (and possibly elsewhere \[[@OFV213C30]\]). This focused investigation also suggests that one cannot assume that *bla*~KPC~ is always responsible for a CRKP phenotype. Therefore, attempts to detect CRKP by the phenotypic MHT without using a broad range of PCR probes seeking to detect other carbapenemases, including but not limited to *bla*~KPC~, are limited. However, when strains who were non-*bla*~KPC~ producers were tested for the presence of other known carbapenemases, it proved to be negative as well. Other mechanisms (eg, ESBLs such as *bla*~CTX-M~ coupled with porin loss mutations \[[@OFV213C14]\]) might be involved in current CRKP epidemiology. Nvertheless, the routine practice in many clinical microbiology laboratories \[[@OFV213C4]\] might not fit the current epidemiology of CRKP anymore.

In this analysis, patients with ST258 strains, considered to be a high-risk clone because of its recognized negative clinical impact, were frequently found to have poor clinical outcomes and high rates of antimicrobial resistance. However, it is notable that poor outcomes and high prevalence of resistance was identified among the small sample of non-ST258 cases as well, including in-hospital mortality among 3 of 7 non-ST258 cases (Table [1](#OFV213TB1){ref-type="table"}). This underscores the fact that the epidemiological significance and clinical impact of non-ST258 strains cannot be dismissed \[[@OFV213C31]\]. Although our high numbers of ST258 strains limits our ability to fully describe the epidemiologic patterns of non-ST258 strains, patients′ background characteristics (ie, demographics, chronic medical conditions, exposures to healthcare settings) appeared to be largely similar between groups, implying that carbapenem-resistant *Enterobacteriaceae* may affect a similar population regardless of the ST, at least in the United States.

We previously described a contemporary outbreak of a colistin-resistant CRKP at this same hospital \[[@OFV213C29]\]. Multilocus sequence typing grouped all of these (original) strains to the ST-258 group, whereas both pulsed-field gel electrophoresis and rep-PCR determined that 2 clonally related groups were involved (similar to the 2 rep-PCR groups seen within ST258 strains from this analysis) \[[@OFV213C29]\]. Since patient-to-patient transmission was demonstrated in a detailed "transmission opportunities analysis" \[[@OFV213C29]\], reflecting clonal spread, this might imply that in epidemic settings, MLST might be a suitable molecular tool to use in outbreak investigations of CRKP.

CONCLUSIONS {#s5}
===========

To conclude, our focused analysis did not identify risk factors or outcomes that were unique to the ST258 CRKP. However, the microbiological features of these strains were significantly different, because ST258 strains are associated with *bla*~KPC~ production and with increased resistances to multiple classes of antimicrobials. Therefore, investigations of CRKP should include the molecular detection of *bla*~KPC~ and other carbapenemase genes, as well as genetic typing. Moreover, *bla*~KPC~ detection should not be used as the sole method to diagnose CRKPs carriage.
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[^1]: Highlighted in bold are statistically significant (*P* \< .05) associations.

[^2]: Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; IQR, interquartile range; PCR, polymerase chain reaction; SD, standard deviation; UTI, urinary tract infection.
